LAUSR

TIGIT (T cell immunoreceptor with immunoglobulin and tyrosine‐based inhibitory motif (ITIM) domain), Vstm3, and VSIG9, are newly recognized immunological checkpoints. They are prominently expressed on CD4+ and CD8+ T cells, tumor‐infiltrating lymphocytes (TILs), natural killer (NK) cells, and regulatory T cells (Tregs). The TIGIT (TIGIT) protein is crucial for immune modulation since it diminishes NK cell populations and hinders T cell activity in cancer patients and experimental models. CD155, the principal ligand of TIGIT in humans, has been recognized as a pivotal target for immunotherapy owing to its interaction with TIGIT. CD155 is linked to the efficacy of anti‐programmed cell death protein 1 (PD‐1) therapy, even without TIGIT expression, underscoring its importance in immune checkpoint suppression. Anti‐TIGIT medicines, either independently or in conjunction with anti‐PD‐1 treatments, have demonstrated potential in augmenting immune responses to malignancies. This review examines the structural and functional characteristics of the TIGIT protein, new developments in anti‐TIGIT drugs, and their prospective use in cancer immunotherapy.